Olaratumab Dosage

Usual Adult Dose for Soft Tissue Sarcoma

15 mg/kg IV over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity; for the first 8 cycles of therapy, this drug is administered with doxorubicin

Premedication: Premedicate with diphenhydramine (25 to 50 mg IV) and dexamethasone (10 to 20 mg IV) prior to olaratumab on Day 1 of cycle 1.

Comments:

• Refer to doxorubicin prescribing information for dosing and dose modifications.

Use: In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Infusion-Related Reaction (IRR):

• Permanently discontinue therapy for Grade 3 or 4 IRRs.
• Interrupt the infusion for Grade 1 or 2 IRRs; after resolution, resume the infusion at 50% of the initial infusion rate.

Neutropenia:

• For neutropenic fever/infection or Grade 4 neutropenia lasting longer than 1 week, discontinue therapy until the absolute neutrophil count is 1,000/microliter or greater and then permanently reduce the dose to 12 mg/kg IV.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Do not administer as an IV push or bolus.
• Do not co-infuse with electrolytes or other medications through the same IV line. -Visually inspect the diluted solution for particulate matter and discoloration prior to administration; if particulate matter or discolorations are present, discard the solution.
• Administer the diluted solution as an IV infusion over 60 minutes; flush the line with sodium chloride 0.09% at the end of the infusion.

Storage requirements:

• The manufacturer product information should be consulted.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

IV compatibility:

• The manufacturer product information should be consulted.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer